According to a small multi-center, phase II trial reported in NEJM, an investigational targeted drug for some patients with metastatic thyroid cancer can induce partial responses.
References and Resources
Sherman S, Wirth W, Droz J, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med. 2008; 359: 31-42.
Sponsored by The Doctor’s Channel